

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3025895

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY AGREEMENT
CONVEYING PARTY DATA	
Name	Execution Date
TOLERA THERAPEUTICS, INC.	08/29/2014
RECEIVING PARTY DATA	
Name:	SILICON VALLEY BANK
Street Address:	3003 TASMAN DRIVE
City:	SANTA CLARA
State/Country:	CALIFORNIA
Postal Code:	95054
PROPERTY NUMBERS Total: 4	
Property Type	Number
Patent Number:	8524234
Patent Number:	8722049
Application Number:	13844434
Application Number:	13946450
CORRESPONDENCE DATA	
Fax Number:	(800)494-7512
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	202-370-4750
Email:	ipteam@nationalcorp.com
Correspondent Name:	DWAYNE C. HOUSTON
Address Line 1:	1025 VERMONT AVENUE NW, SUITE 1130
Address Line 2:	NATIONAL CORPORATE RESEARCH, LTD.
Address Line 4:	WASHINGTON, D.C. 20005
ATTORNEY DOCKET NUMBER:	L078726
NAME OF SUBMITTER:	ROBIN DUNN
SIGNATURE:	/Robin Dunn/
DATE SIGNED:	09/17/2014
Total Attachments: 8	
source=Patent Cover Sheet and IPISA - Executed#page2.tif	
source=Patent Cover Sheet and IPISA - Executed#page3.tif	

source=Patent Cover Sheet and IPSA - Executed#page4.tif
source=Patent Cover Sheet and IPSA - Executed#page5.tif
source=Patent Cover Sheet and IPSA - Executed#page6.tif
source=Patent Cover Sheet and IPSA - Executed#page7.tif
source=Patent Cover Sheet and IPSA - Executed#page8.tif
source=Patent Cover Sheet and IPSA - Executed#page9.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement ("Agreement") is entered into as of the August 29, 2014 by and between SILICON VALLEY BANK ("Bank") and TOLERA THERAPEUTICS, INC. ("Grantor").

RECITALS

A. Bank has agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the "Loans") in the amounts and manner set forth in that certain Loan and Security Agreement by and between Bank and Grantor dated June 27, 2013 (as the same has been or may further be amended, modified or supplemented from time to time, the "Loan Agreement"; capitalized terms used herein are used as defined in the Loan Agreement). Bank is willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Bank a security interest in certain Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Bank a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

1. Grant of Security Interest. To secure its obligations under the Loan Agreement, Grantor grants and pledges to Bank a security interest in all of Grantor's right, title and interest in, to and under its intellectual property (all of which shall collectively be called the "Intellectual Property Collateral"), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the "Copyrights");

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "Trademarks");

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the "Mask Works");

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this Agreement upon request by Bank.

3. Authorization. Grantor hereby authorizes Bank to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement, and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

4. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Bank with respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

5. Representations and Warranties. Grantor represents and warrants as follows as of the date hereof: Exhibit A sets forth a list of all of Grantor's registered copyrights and applications for registration of copyrights; Exhibit B sets forth a list of all of Grantor's patents and patent applications; Exhibit C sets forth a list of all of Grantor's federally registered trademarks and applications for federal registration of trademarks; and Exhibit D sets forth a list of all of Grantor's registered mask works and applications for registration of mask works.

6. Execution in Counterparts. This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or in electronic (i.e., "pdf" or "tif" format) shall be effective as delivery of a manually executed counterpart of this Agreement.

7. Successors and Assigns. This Agreement will be binding on and shall inure to the benefit of the parties hereto and their respective successors and assigns.

8. Governing Law. This Agreement and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the laws of the United States and the State of California, without giving effect to any choice or conflict of law provision or rule (whether of the State of California or any other jurisdiction).

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

TOLERA THERAPEUTICS, INC.

By:

Title:


PRESIDENT + CEO

BANK:

SILICON VALLEY BANK

By:

Title:



Vice President

EXHIBIT A

Copyrights

Description

Registration/
Application
Number

Registration/
Application
Date

None.

EXHIBIT B

US Patents and Applications

<u>Description</u>	<u>Registration/ Application Number</u>	<u>Registration/ Application Date</u>
Antibody for Selective Inhibition of T-Cell Responses	8,524,234	09/03/2013
Antibody and Methods for Selective Inhibition of T-Cell Responses	8,722,049	05/13/2014
Antibody and Methods for Selective Inhibition of T-Cell Responses	13/844,434	03/15/2013
Antibody and Methods for Selective Inhibition of T-Cell Responses	13/946,450	07/19/2013

Foreign Patent Applications

<u>Description</u>	<u>Registration/ Application Number</u>	<u>Registration/ Application Date</u>
Antibody and Methods for Selective Inhibition of T-Cell Responses (PCT)	PCT/US2012/063583	11/05/2012
Antibody and Methods for Selective Inhibition of T-Cell Responses (Australia)	2012332193	11/05/2012
Antibody and Methods for Selective Inhibition of T-Cell Responses (Brazil)	1120140105324	11/05/2012
Antibody and Methods for Selective Inhibition of T-Cell Responses (Canada)	2853687	11/05/2012
Antibody and Methods for Selective Inhibition of T-Cell Responses (China)	201280066004.9	11/05/2012
Antibody and Methods for Selective Inhibition of T-Cell Responses (Europe)	12845538.3	11/05/2012
Antibody and Methods for Selective Inhibition of T-Cell Responses (Israel)	232269	11/05/2012
Antibody and Methods for Selective Inhibition of T-Cell Responses (Japan)	2014-540186	11/05/2012
Antibody and Methods for Selective Inhibition of T-Cell Responses (Korea)	10-2014-7015219	11/05/2012
Antibody and Methods for Selective Inhibition of T-Cell Responses (Mexico)	MX/a/2014/005358	11/05/2012

EXHIBIT C

Trademarks

Description

Registration/
Application
Number

Registration/
Application
Date

None.

EXHIBIT D

Mask Works

Description

Registration/
Application
Number

Registration/
Application
Date

None.